Masked Hypertension Clinical Trial
The primary purpose of the study is to estimate the target organ protection after 12 months
of antihypertensive treatment in masked hypertension patients with at least one kind of
target organ damage (left ventricular hypertrophy, large arterial stiffness and
microalbuminuria). Improvement was defined as the relevant parameter back to normal or
declined at least 20%.
The secondary objectives include: blood pressure lowering effect, target organ damage parameters improvement, and the incidence rate of all cause death and cardiovascular events (stroke and myocardia infraction).
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention
|Source||Shanghai Institute of Hypertension|
|Contact||Yan Li, Professor|
|Status||Not yet recruiting|
|Start date||November 2016|
|Active, not recruiting||